aibioCytoDyn secures $30 million stock purchase commitment from Yorkville Advisors Global
Tickers CYDY
CytoDyn can sell up to $30 million of common stock to Yorkville Advisors Global over 36 months, at its own discretion and with no warrants attached. The release names no placement agent or counsel, and the annual report says the company will pursue non-dilutive financing in addition to traditional fundraising.
Key facts
- Company
- CytoDyn Inc. (OTC: CYDY)
- News type
- Financings
- Primary source
- CytoDyn Inc. 8-K (2025-11-03)
CytoDyn Inc. (OTCQB: CYDY) said in a press release filed as an exhibit to a Form 8-K on November 3, 2025 that it had secured a $30 million funding commitment from Yorkville Advisors Global. Under the agreement, CytoDyn has the right to sell, and Yorkville has the obligation to purchase, up to $30 million of its common stock over the next 36 months.
CytoDyn controls the timing of every sale to Yorkville at its sole discretion. The release says there are no warrants, derivatives or other share classes tied to the arrangement. It also says CytoDyn is not required to use any of the $30 million, that there are no minimum commitments or minimum-use penalties, and that the arrangement does not restrict its operating activities.
The release names no placement agent, underwriter, financial advisor or counsel for the arrangement. Yorkville is the purchaser. The release does not state the price at which Yorkville would purchase shares, a discount to the market or a minimum share price, and it does not say how many shares the $30 million would cover at current prices.
What the company says it will do with it
Chief Financial Officer Robert E. Hoffman said the company will use the commitment to further develop a program centered on the ability of leronlimab to upregulate PD-L1. The release gives no data supporting that mechanism. The annual report's business section describes the strategy differently, as a Phase II trial of leronlimab in relapsed or refractory microsatellite stable colorectal cancer, further solid-tumor studies including metastatic triple-negative breast cancer, and a longer-acting version of the drug. The annual report's strategy list does not mention PD-L1.
Hoffman also said the structure "allows us continued flexibility as we look to bring in additional capital," whether through more financings or strategic partnerships. The release describes CytoDyn as a clinical-stage oncology company advancing leronlimab, a humanized monoclonal antibody that targets the CCR5 receptor, with potential in triple-negative breast cancer and metastatic colorectal cancer. The release lists ir@cytodyn.com as the corporate contact and Russo Partners, LLC as the media contact.
Dilution against the company's stated preference
The annual report, filed July 25, 2025 for the fiscal year ended May 31, 2025, says the company "may need significant additional funding" to carry out its strategy in full. It says that, beyond traditional fundraising, it will pursue non-dilutive financing such as license agreements, co-development or strategic partnerships.
A common stock sale to Yorkville is equity, not a license or partnership. Each share sold under the commitment adds to the shares outstanding. The release does not say how many shares the company has issued to date under the arrangement, and it does not give a timetable for any sale.
What the release leaves out
The release gives no cash balance, no net loss and no runway, so a reader cannot see how much of the $30 million the company would need in the next year. It does not give a recent closing price for the OTCQB-quoted stock, and it does not discuss how the arrangement would change the share count over the 36-month period. The annual report says the company may need significant additional funding for its full strategy, and the release does not link the commitment to any dated milestone or to a trial result. The release points to no trial data for the PD-L1 program.